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SUMMARY
 
In an unselected cohort of 282 children, serum immunoglobulin (Ig) concentrations were determined
shortly after the first presentation with one or more unprovoked epileptic seizures and before the start
of treatment with anti-epileptic drugs (AEDs), and after 9–18 months of AEDs use. At intake, IgA,
IgG1, IgG2 and IgG4 concentrations were significantly higher than published reference values in
healthy age-matched controls. In a subset of 127 children, Ig levels at intake were compared with those
after AEDs use for 9–18 months. IgA and IgG4 levels had decreased significantly to normal concen-
trations, but IgG1 and IgG3 levels increased significantly. To determine the influence of AEDs, Ig levels
in children who used carbamazepine or valproic acid monotherapy were analysed separately. The use of
carbamazepine was associated with a significant decrease of IgA and IgG4 levels, and the use of valproic
acid with a significant decrease of IgA and increase of IgG1 levels. In conclusion, humoral immunity is
already altered in children shortly after the first presentation with epileptic seizures. Whether this is the
consequence of an exogenous event, and to what extent this is related to an interaction of the central
nervous system and the immune system, remains to be evaluated. Treatment with AEDs, such as car-
bamazepine and valproic acid, is associated with significant changes of Ig (sub)class concentrations.
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INTRODUCTION
 
Based on the bidirectional interaction between the central ner-
vous system (CNS) and the immune system, it is attractive to
speculate that immune mechanisms may be involved in the patho-
genesis of at least some forms of epilepsy or that epileptic seizures
may affect the immune system indirectly [1,2]. The implication of
autoimmune mechanisms in the development of epilepsy has
been demonstrated most convincingly for Rasmussen’s encepha-
litis, in which antiglutamate receptor 3 antibodies reacting with
neuronal antigen probably play a central role in the disease pro-
cess [3]. Another argument for immunological mechanisms being
involved is the observation that some patients suffering from
this and other forms of intractable epilepsy, i.e. West syndrome,
Lennox–Gastaut syndrome and Landau–Kleffner syndrome, may
benefit from treatment with intravenous immunoglobulins (IVIg)
[4,5]. The mechanism of action of IVIg remains, however, cur-
rently unknown.
Many reports have been published concerning the effects of
the treatment with anti-epileptic drugs (AEDs), e.g. phenytoin
[6–9], carbamazepine [10–13] and valproic acid [14–16], on
humoral and cellular immunity. From these studies, it became
clear that a reversible induction of a selective IgA deficiency
might occur in some patients receiving phenytoin [8], and that
carbamazepine medication might be associated with selective
reduction of the IgG2 subclass concentration [11]. However, use-
ful interpretation of the results of the majority of the publications
is hampered by the lack of data obtained shortly after the onset of
seizures and before the start of treatment. Furthermore, the stud-
ied populations are relatively small, limited mainly to adult
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patients, or contained a heterogeneous population of adults and
children.
We investigated serum immunoglobulins in a large cohort of
children from their first presentation with unprovoked epileptic
seizures onwards. Here, we present quantitative data of the major
immunoglobulin (Ig) isotypes and IgG subclasses in serum sam-
ples obtained at intake and after use of AEDs for 9–18 months.
The effects of carbamazepine or valproic acid given as monother-
apy on Ig serum levels were investigated separately.
 
METHODS
 
Patients
 
During an inclusion period of 4 years, 556 children aged 1
month to 16 years presenting in one of the participating hospi-
tals with one or more newly diagnosed unprovoked seizures or
at least one status epilepticus were enrolled in the Dutch Study
of Epilepsy in Childhood. Detailed inclusion and exclusion cri-
teria and investigations performed are reported elsewhere [17–
19]. Only if a child had experienced two or more seizures did
the paediatric neurologist consider whether to treat the child
and select the AEDs. Valproic acid and carbamazepine were
used as first-line drugs in all children [17]. The epilepsy was
judged not to be controlled adequately if at least two first-line
and one second-line drug were tried up to maximum tolerated
dosages unsuccessfully.
Three paediatric neurologists involved in the study classi-
fied independently the seizures and epilepsy syndromes as
idiopathic, remote symptomatic or cryptogenic according to the
revised classifications of the International League Against Epi-
lepsy (ILAE) [20,21]. Idiopathic epilepsies are epileptic syn-
dromes with particular clinical characteristics and with specific
EEG findings. They are of unknown origin but have a pre-
sumed genetic aetiology. Remote symptomatic epilepsies are
considered the consequence of a known or suspected disorder of
the central nervous system resulting in a static encephalopathy.
Cryptogenic epilepsies are epilepsies of unknown origin that do
not conform the criteria for the symptomatic or idiopathic
categories [22]. All mentally retarded children with epilepsy of
unknown aetiology were classified as having remote symptom-
atic epilepsy. Outcome was assessed with the help of the termi-
nal remission: if the child had been seizure-free for 12 months or
more at the end of the follow-up of 5 years, outcome was quali-
fied as ‘good’, if 6–12 months as ‘fair’, and if less than 6 months
as ‘poor’ [19].
The study had been approved by the medical ethical commit-
tees of all participating hospitals. Parents or caregivers gave their
written informed consent.
 
Immunology
 
For several reasons, e.g. protocol deviations by the paediatric neu-
rologist and refusal of the parents, serum samples were not avail-
able from 274 of the 556 children who met the inclusion criteria
and were enrolled in the Dutch Study of Epilepsy in Childhood.
Samples were obtained from the remaining 282 children at intake
alone (
 
n
 
 
 
=
 
 155) or at intake and after the use of AEDs for 9–
18 months (
 
n
 
 
 
=
 
 127) and stored at 
 
-
 
20
 
∞
 
C. Serum concentrations of
IgM and IgA were quantified by single radial immunodiffusion
(Endoplates, Kallestad, Austin, TX, USA) or nephelometry (BN
100 nephelometer, Behring, Marburg, Germany; antisera from
Behring). The concentrations of IgG1, IgG2, IgG3 and IgG4 were
measured by dot-immunobinding assay as previously described
[23] or nephelometry (BN 100 nephelometer; antisera from the
Central Laboratory of the Netherlands Red Cross Blood Trans-
fusion Service (CLB), Amsterdam, the Netherlands).
To validate that the reported median and range of Ig
(sub)class concentrations in serum samples of age-matched con-
trols (reference values for IgM and IgA: Cejka 
 
et al.
 
 1974 [24], ref-
erence values for the IgG subclasses: CLB, 1997 [25]) could be
applied in our experimental setting, serum samples obtained from
76 healthy children were analysed. This control group consisted of
sibling donors for recipients of a HLA-identical bone marrow
graft that were transplanted at the Department of Paediatrics of
the Leiden University Medical Centre.
 
Statistical analysis
 
Normal distribution was tested with the Kolmogorov–Smirnov
test. Clinical characteristics were compared between the children
from whom a blood sample was taken at intake and the children
from whom no blood sample was taken, and between children
from whom two blood samples were obtained (at intake and after
AEDs use for 9–18 months) and children from whom only a
blood sample was obtained at intake using the Pearson 
 
c
 
2
 
 test
(sex, aetiology, distribution epilepsy syndromes) and the Mann–
Whitney rank-sum test (age at onset, Ig ratios). Furthermore,
differences in clinical characteristics between the distinctive
aetiologies were analysed with the Kruskal–Wallis test (age at
taking blood sample and outcome) and the Pearson 
 
c
 
2
 
 test (dis-
tribution epilepsy syndromes).
Because normal ranges of Ig (sub)classes are age-dependent
for each (sub)class, we corrected for age by calculating ratios: the
observed Ig (sub)class concentration of each child was divided
by the reported median Ig (sub)class concentration in healthy
children of the corresponding age group [24,25]. Using the Wil-
coxon signed-ranks test, we tested whether the calculated ratios
in the cohort of which a blood sample was obtained at intake
differed significantly from 1 (if the ratio was 1, the observed Ig
concentration equalled the median concentration of the corre-
sponding age), and whether Ig ratios differed between intake
and after AEDs use for 9–18 months. Results were adjusted for
multiple testing with the Bonferroni correction. Furthermore, we
tested whether children with Ig concentrations outside the nor-
mal range of the corresponding age group differed from children
with Ig concentrations within the normal range with regard to
age, aetiology, distribution of epilepsy syndromes and outcome
applying the Pearson 
 
c
 
2
 
 test (aetiology, distribution of epilepsy
syndromes) and the Mann–Whitney rank-sum test (age, out-
come). We also tested whether the Ig ratios differed between the
group with one seizure and the group with multiple seizures
(Mann–Whitney rank sum test) or between the different epi-
lepsy syndromes as classified by the ILAE (Kruskal–Wallis test)
[21].
 
RESULTS
 
At intake, a blood sample was taken of 282 (51%; 133 boys, 149
girls) of the 556 children included in the Dutch Study of Epilepsy
in Childhood. The median period between the first seizure and
obtaining this blood sample was 69 days (range 0 days
 
-
 
6 years).
No significant differences were found in sex, aetiology and epi-
lepsy syndrome distribution between the children from whom a
blood sample was taken and the children from whom no blood
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sample was taken. Children from whom no blood sample was
obtained at intake (
 
n
 
 
 
=
 
 274) had a significantly lower age at the
onset of their epilepsy than children from whom a blood sample
was obtained at intake (
 
n
 
 
 
=
 
 282; median age at onset 5·1 and
6·1 years, respectively; 
 
P
 
 
 
<
 
 0·05).
Of the 282 children in our cohort, 164 (58%) suffered from
seizures of idiopathic aetiology, 44 (16%) from seizures of cryp-
togenic aetiology and 74 (26%) from seizures of remote symp-
tomatic aetiology (Table 1). Twenty-eight children in our cohort
experienced a single, unprovoked seizure. Epilepsy syndrome dis-
tribution differed significantly between the three groups
(
 
P
 
 
 
<
 
 0·001): children with epilepsy of idiopathic aetiology suffered
relatively more often from generalized epilepsy and less from
localization-related epilepsy than the other two groups, and chil-
dren with epilepsy of cryptogenic aetiology suffered relatively less
frequently from generalized epilepsy than children with epilepsy
of remote symptomatic aetiology (
 
P
 
 
 
<
 
 0·001, Table 1). Further-
more, outcome differed significantly between the three groups
(
 
P
 
 
 
<
 
 0·001): children with idiopathic aetiology had a significantly
better outcome than both children with cryptogenic aetiology and
children with remote symptomatic aetiology (
 
P
 
 
 
<
 
 0·001, data not
shown).
 
Immunoglobulin levels at intake
 
At intake, levels of IgA, IgG1, IgG2 and IgG4 were significantly
higher in our cohort of 282 children than the reported median Ig
(sub)class levels of healthy children of the corresponding ages
(the ratios were significantly higher than 1, 
 
P
 
 
 
<
 
 0·001, Fig. 1).
Sixty-three children (22%) had an IgG1 concentration above
the upper limit of the normal range for the corresponding age.
For the other Ig (sub)classes, up to 6% of the children had con-
centrations below the lower limit, and up to 9% had concentra-
tions above the upper limit of the normal range. The numbers of
children with a serum concentration outside the normal range
were: for IgM, 16 below the lower limit and 11 above the upper
limit; for IgA, 18 and 18; for IgG2, 8 and 26; for IgG3, 1 and 0;
and for IgG4, 3 and 13, respectively (Fig. 1, grey areas). Two
children had an absolute IgA deficiency, and one other child an
absolute IgG3 deficiency. Aetiology (i.e. idiopathic, remote
symptomatic, cryptogenic), epilepsy syndrome distribution (i.e.
localization-related, generalized, single seizure), age at intake
and outcome were not significantly different between children
with Ig concentrations below the lower limit or above the upper
limit of the normal range and those with Ig concentrations
within the normal range. This observation holds for all
 
Fig. 1.
 
Ratio between the observed immunoglobulin (Ig) (sub)class concentrations in children from whom a blood sample was obtained
at intake (
 
n
 
 
 
=
 
 282) and the published median of normal levels [24,25]. IgA, IgG1, IgG2 and IgG4 concentrations were significantly higher
in our cohort than the reported median Ig (sub)class concentrations of healthy children of the corresponding ages (*
 
P
 
 
 
<
 
 0·001). Grey areas
represent children with Ig (sub)class concentrations below the lower limit or above the upper limit of the normal range. The median ratio
of all Ig (sub)classes as well as the range (between brackets) are given. 
 
>
 
: ratio 
 
≥
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Table 1.
 
Clinical characteristics of the children from whom a blood sample was taken at intake (
 
n
 
 
 
=
 
 282)
Idiopathic Cryptogenic Remote  symptomatic Total
Number (%) 164 (58·2) 44 (15·6) 74 (26·2) 282 (100·0)
Median age at taking blood sample (year) 6·5 7·1 5·4 6·3
Distribution of epilepsy syndromes
 
a
 
Localization-related (%) 22 (13·4)
 
b
 
41 (93·2) 39 (52·7) 102 (36·2)
Generalized (%) 114 (69·5) 3 (6·8) 31 (41·9) 148 (52·5)
Other (%) 3 (1·8) 1 (1·4) 4 (1·4)
Single seizure (%) 25 (15·2) 3 (4·1) 28 (9·9)
 
a
 
Distribution according to the revised classification of the International League Against Epilepsy, 1989 [21]. 
 
b
 
Epilepsy syndrome distribution differed
significantly between groups (
 
P
 
 
 
<
 
 0·001).
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(sub)classes with one exception. Children with an IgG1 concen-
tration above the upper limit of the normal range were signifi-
cantly younger than children with an IgG1 concentration within
the normal range (median age at intake 4·5 and 6·9 years,
respectively, 
 
P
 
 
 
<
 
 0·01).
At the time of the first blood sampling the seizure frequency
was known in 163 of the 282 patients. Ig levels did not differ sig-
nificantly between children who had experienced a single seizure
and those who had multiple seizures. However, there was a
significant negative correlation between the overall seizure
frequency and the IgG1 level corrected for age (
 
P
 
 
 
=
 
 0·003), indi-
cating that IgG1 was lower in children with higher seizure fre-
quency. For the other Ig (sub)classes no significant correlations
were found. No significant differences in Ig were observed
between the different epilepsy syndromes as classified by the
ILAE (including six children with West syndrome and two with
Lennox–Gastaut syndrome) [21].
In our control group of 76 healthy children, who were bone
marrow transplant donors, none of the median concentrations
of the Ig classes and IgG subclasses were significantly different
from those reported in healthy children of the corresponding
age group. On an individual basis, abnormal concentrations of
one or more of the Ig classes and IgG subclasses were detected
only in sporadic cases, and only 5% of the children in our control
group showed an increase of IgG1 (data not shown).
 
Immunoglobulin levels after using anti-epileptic drugs for
9–18 months
 
In 127 (45%) of the 282 children, a second blood sample was
obtained after 9–18 months of continuous AEDs use. Median age
at onset of epilepsy, sex, aetiology, distribution of epilepsy syn-
dromes and median Ig ratios at intake did not differ significantly
between these children and those from whom no second blood
sample was taken.
After using AEDs for 9–18 months, IgA (
 
P
 
 
 
<
 
 0·001) and IgG4
(
 
P
 
 
 
<
 
 0·01) levels had decreased significantly compared to the
levels at intake; IgG1 (
 
P
 
 
 
<
 
 0·001) and IgG3 (
 
P
 
 
 
<
 
 0·01) levels had
significantly increased (Fig. 2). The significant decrease in IgA
and IgG4 levels led to normalization of these levels with a
median ratio of approximately 1; there was no difference in the
number of children with IgA or IgG4 concentrations below the
lower limit of the normal range at intake and after AEDs use for
9–18 months. No new cases with an absolute IgA deficiency were
observed. The significant increase of IgG1 after 9–18 months of
AEDs use, however, led to 38% of the 127 children having an
IgG1 concentration above the upper limit of the normal range
(Fig. 2), which was significantly more than before treatment
(24%, 
 
P
 
 
 
<
 
 0·01). The change in IgG1 levels over time did not
differ significantly between different aetiologies or different
outcomes. Children with generalized epilepsy, however, showed a
significant increase of the IgG1 level (
 
P
 
 
 
<
 
 0·001) while the
 
Fig. 2.
 
Ratio between the observed immunoglobulin (Ig) (sub)class concentrations in children (
 
n
 
 
 
=
 
 127) from whom a blood sample was obtained at
intake (upper panel) and after 9–18 months of AEDs use (lower panel), and the reported median of normal levels [24,25]. IgA (*
 
P
 
 
 
<
 
 0·001 and IgG4
(**
 
P
 
 
 
<
 
 0·01) levels had decreased significantly as compared to the levels at intake; IgG1 (*
 
P
 
 
 
<
 
 0·001) and IgG3 (**
 
P
 
 
 
<
 
 0·01) levels showed a significant
increase. Grey areas represent children with Ig (sub)class concentrations below the lower limit or above the upper limit of the normal range. The median
ratio of all Ig (sub)classes as well as the range (between brackets) are given. 
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median IgG1 level remained approximately the same in children
with localization-related epilepsy. Furthermore, aetiology, out-
come and epilepsy syndrome distribution were not significantly
different between children with an IgG1 concentration above the
upper limit of the normal range and children with an IgG1 con-
centration within the normal range. The age at the time of the
second blood sample was, however, significantly lower in children
with an IgG1 concentration above the upper limit of the normal
range than in children with an IgG1 concentration within the nor-
mal range (median age 4·3 and 9·5 years, respectively, 
 
P
 
 
 
<
 
 0·001).
The increase of IgG3 led to 2% of the children having an IgG3
concentration above the upper limit of the normal range after 9–
18 months of AEDs use (Fig. 2).
 
Anti-epileptic drugs
 
To determine more closely the influence of distinct anti-epileptic
drugs, changes of Ig concentrations in children that used carbam-
azepine or valproic acid as monotherapy were investigated. After
9–18 months, 34 (27%) children had continuously received car-
bamazepine monotherapy and 60 (47%) valproic acid monother-
apy. Of the other 33 children, seven used ethosuximide, two
vigabatrin, one phenytoin and 23 had polytherapy. Because of the
small size of the groups, the influence of these anti-epileptic drugs
on the immunoglobulins could not be determined.
Of the 34 children using carbamazepine, seven (21%) suffered
from epilepsy of idiopathic aetiology, 13 (38%) from epilepsy of
cryptogenic aetiology and 14 (41%) from epilepsy of remote
symptomatic aetiology. Thirty-one (91%) had localization-related
epilepsy and three (9%) generalized epilepsy. In children on car-
bamazepine monotherapy, IgA (
 
P
 
 
 
<
 
 0·01) and IgG4 (
 
P
 
 
 
<
 
 0·01)
levels had decreased significantly over time, leading to normaliza-
tion of the median IgA and IgG4 levels (Fig. 3a).
Of the 60 children using valproic acid, 44 (73%) suffered from
epilepsy of idiopathic aetiology, three (5%) from epilepsy of cryp-
togenic aetiology and 13 (22%) from epilepsy of remote symp-
tomatic aetiology. Seven (12%) had localization-related epilepsy
and 52 (87%) generalized epilepsy. In children on valproic acid
monotherapy, IgA levels showed a significant decrease to normal
concentrations with a median ratio of approximately 1 (
 
P
 
 
 
<
 
 0·01)
and a significant increase of IgG1 levels (
 
P
 
 
 
<
 
 0·001, Fig. 3b). After
9–18 months of treatment, 26 (43%) of these children had an
IgG1 above the upper limit of the normal range compared to 18
(30%) at intake. This difference was not statistically significant. To
investigate whether the observed increase in IgG1 was due
merely to the use of valproic acid, it was tested whether IgG1 lev-
els decreased after discontinuation of valproic acid. Blood sam-
ples were taken from 10 children who were excluded from the
analysis described above because they discontinued AEDs within
9 months, just before discontinuation of valproic acid and
4–11 months after discontinuation. IgG1 levels significantly
decreased after discontinuation of valproic acid (
 
P
 
 
 
<
 
 0·05, data
not shown). Furthermore, we investigated whether IgG1 levels
differed between children that had polytherapy with (
 
n
 
 
 
=
 
 18) or
without (
 
n
 
 
 
=
 
 5) valproic acid. These groups did not differ signifi-
cantly in age, aetiology, epilepsy syndrome distribution, outcome
and IgG1 levels at intake. After using therapy for 9–18 months,
however, IgG1 levels were significantly higher in the group that
used polytherapy with valproic acid than in the group without val-
proic acid (
 
P
 
 
 
<
 
 0·05, data not shown).
When comparing Ig levels between children using carbam-
azepine and children using valproic acid, it was observed that IgM
levels were significantly lower in the group using carbamazepine
than in the group using valproic acid (
 
P
 
 
 
<
 
 0·01). Furthermore,
IgG1 levels were significantly higher in the group using valproic
acid than in the group using carbamazepine (
 
P
 
 
 
<
 
 0·01). The other
Ig levels did not differ significantly between the two groups.
 
DISCUSSION
 
This study focuses on a large cohort of children with one or more
unprovoked epileptic seizures followed prospectively from their
first visit to a specialist clinic. Serum samples were already avail-
able early after the first presentation with seizures and before the
initiation of any treatment with AEDs. In addition, a second
serum sample was available in about half of the patients at follow-
up after 9–18 months of AEDs use.
Since median concentrations of the Ig (sub)classes in serum
samples of our control group of 76 healthy children were not sig-
nificantly different from the reported median values in healthy
age-matched controls [24,25], our experimental approach can be
considered to be valid. Therefore, the observed increase in the
median serum concentration of IgA, IgG1, IgG2 and IgG4 (cor-
rected for age) in our cohort of children with newly diagnosed epi-
lepsy indicates that disturbances of humoral immunity are already
present before the initiation of medical treatment, and that these
disturbances are independent from aetiology and the type of epi-
lepsy syndrome. However, increased IgG1 concentrations were
especially detected in young children. It has to be realized that the
children from whom no blood sample was taken at intake were sig-
nificantly younger than the children from whom this blood sample
was obtained. Therefore, the influence of epilepsy on IgG1 might
be underestimated because of a sampling bias.
To our knowledge, this is the first study in which only children
are enrolled and in which serum Ig concentrations were already
measured within a short period (median: 69 days) after the first
presentation with epileptic seizures and before the start of AEDs.
Some other reports have also described alterations of humoral
immunity in epilepsy patients who were not on AEDs [13,15],
whereas Lenti 
 
et al. did not observe alterations in untreated
patients [26]. Unfortunately, the time period passed between the
first presentation of seizures and the measurement of serum Ig
concentrations was not indicated in these papers.
The underlying mechanism for the observed disturbances of
humoral immunity in children at an early stage of epilepsy
remains unknown. One can speculate that infections might have
triggered the immune response, as suggested by the increased
serum concentrations of various IgG subclasses and IgA, and con-
comitantly might have caused a disturbance of the blood–brain
barrier. Exposure of formerly hidden antigens of the CNS to the
immune system might lead consequently to seizures possibly
mediated by cross-reactive autoantibodies produced in response
to the infectious agents or by antibodies induced by antigens of
the CNS itself. However, in our study cohort there is no formal
indication for such an order of events. At intake, each of the 282
children showed normal leucocyte counts and a normal leucocyte
differentiation, suggesting that infections in this population at
that time point were very rare. On the other hand, 5·3% of the
children in our study cohort showed an increased serum concen-
tration of IgD at intake, in comparison with none of the children
in the control group (data not shown). At the Department of
Paediatrics of the Leiden University Medical Centre, elevated
levels of IgD are particularly detected in children suffering from
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Fig. 3. Ratio between the observed immunoglobulin (Ig) (sub)class concentrations at intake (upper panel) and after 9–18 months (lower
panel) of (a) carbamazepine (n = 34) or (b) valproic acid (n = 60) monotherapy, and the reported normal levels [24,25]. In children using
carbamazepine, IgA and IgG4 levels showed a significant decrease (**P < 0·01). The children that used valproic acid had a significant
decrease of IgA levels (**P < 0·01) and a significant increase of IgG1 levels (*P < 0·001). Grey areas represent children with Ig (sub)class
concentrations below the lower limit or above the upper limit of the normal range. The median ratio of all Ig (sub)classes as well as the
range (between brackets) are given. >: ratio ≥ 3·4.
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recurrent respiratory tract infections or autoimmune diseases
(e.g. juvenile idiopathic arthritis). We did not find a correlation
between an increase of IgG1 and an elevation of IgD in our
cohort. Because no clinical information about the presence of, e.g.
respiratory infections was obtained at intake, no statement can be
made about the relation between infections and epilepsy in our
cohort. As a first step to investigate the possible aetiology of the
various forms of childhood epilepsy more closely, it will be rele-
vant to measure antibody titres in these sera against bacterial and
viral micro organisms and against a panel of autoantigens.
The lack of an association between the occurrence of abnor-
mally low or high concentrations of serum Ig classes or IgG sub-
classes early in the disease and the outcome (terminal remission)
of the epilepsy measured 5 years after intake, indicates that Ig lev-
els before the start of AEDs treatment are not useful as markers
for the early recognition of patients with intractable epilepsy. Ig
concentrations at the time of the second blood sampling were also
not significantly different in children with different outcomes.
The decrease of IgA and IgG4 and increase of IgG1 and IgG3
after 9–18 months of AEDs treatment in the whole study popu-
lation of 127 children can, at least partially, probably be attributed
to the effect of medication. In children on carbamazepine mono-
therapy for 9–18 months, IgA and IgG4 concentrations showed a
decrease in comparison with the level before the initiation of
treatment. Regarding the decrease of IgA, our observation is in
line with an earlier report concerning adults on carbamazepine
[10]. However, in our study cohort we did not find a significant
decrease of IgM as reported previously by others in adults [10]
and children [13]. Furthermore, our data are contradictory to
other reports in adults [12] and children [26], which showed no
effect of carbamazepine treatment on serum concentrations of
any of the major Ig isotypes. In a combined population of adults
and children, Gilhus and Lea have described an association
between carbamazepine monotherapy and a decrease of IgG2,
while IgG4 remained unaffected [11]. Interpretation of the diver-
gence of these observations from our results is impossible, due to
the lack of data obtained before the start of treatment in most of
the studies, the variable composition of the study population
regarding aetiology and type of epilepsy syndromes, the usually
small size of the study groups and the variable duration of med-
ication use ranging from months to over 10 years. Moreover,
information on the start of medication related to the onset of epi-
lepsy is not available from most of the published studies.
Our results indicate that valproic acid, as monotherapy or as
part of a combined therapy, is associated with an increase of IgG1.
In addition, in children on monotherapy with valproic acid, IgA
decreased to normal levels. Data in the literature on the effect of
valproic acid on the concentration of serum Ig classes are scarce
and even lacking when IgG subclasses are concerned [14–
16,26,27]. Although the same constraints hold for these studies as
indicated above for the studies on carbamazepine, the common
observation arose in these studies that the concentrations of the
major Ig isotypes in serum are unaffected in patients treated with
valproic acid. Unfortunately, we have no information about the
change in serum immunoglobulin concentrations over time in
non-treated patients with epilepsy. Therefore, we cannot exclude
that the observed changes are caused predominantly by the epi-
lepsy itself and not by the use of AEDs. We observed, however,
that IgG1 levels decreased significantly after withdrawal of valp-
roic acid, leading to the conclusion that valproic acid was indeed
responsible for the increase of IgG1.
It is attractive to speculate that the divergent development of
Ig (sub)class concentration in children treated with carbam-
azepine and valproic acid, respectively, might be associated with a
different effect of these AEDs on B cell maturation (i.e. Ig isotype
switching), either directly at the B cell level or at the level of reg-
ulatory T lymphocytes.
In conclusion, humoral immunity is already altered in chil-
dren early after the first presentation with epileptic seizures.
Whether this is the consequence of an exogenous event, such
as the occurrence of infection, and to what extent this is
related to an interaction of the CNS and the immune system
remains to be evaluated. Treatment with carbamazepine and
valproic acid is associated with significant changes of serum
concentrations of distinct Ig isotypes and IgG subclasses. To
outline the clinical relevance of altered immunity in children
with epilepsy, further research has to be performed in which
the medical history of each child regarding infections is
recorded from intake onwards and in which serum Ig concen-
trations of non-treated children are compared over time with
those of children using AEDs.
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